Compare ALNT & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALNT | DRUG |
|---|---|---|
| Founded | 1962 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.3M | 856.4M |
| IPO Year | N/A | N/A |
| Metric | ALNT | DRUG |
|---|---|---|
| Price | $63.31 | $86.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $50.33 | ★ $106.75 |
| AVG Volume (30 Days) | 131.3K | ★ 274.2K |
| Earning Date | 03-04-2026 | 02-13-2026 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | ★ 28.52 | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | ★ $533,134,000.00 | N/A |
| Revenue This Year | $4.80 | N/A |
| Revenue Next Year | $5.42 | N/A |
| P/E Ratio | $56.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.25 | $23.18 |
| 52 Week High | $65.41 | $123.75 |
| Indicator | ALNT | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 67.99 | 51.74 |
| Support Level | $61.65 | $81.72 |
| Resistance Level | $65.41 | $91.00 |
| Average True Range (ATR) | 2.53 | 7.87 |
| MACD | 0.32 | -0.80 |
| Stochastic Oscillator | 82.15 | 14.67 |
Allient Inc, formerly Allied Motion Technologies Inc designs, manufactures, and sells precision and specialty motion control components and systems. The firm primarily caters to the vehicle, medical, aerospace and defense, and electronics and industrial, pumps, and robotics sectors. It mainly operates and sells across the United States, Canada, South America, Europe, and Asia. Its products and solutions include nano precision positioning systems, servo control systems, motion controllers, digital servo amplifiers and drives, brushless servo, torque, and coreless motors, brush motors, integrated motor drives, gear motors, gearing, incremental and absolute optical encoders, active (electronic) and passive (magnetic) filters for power quality and harmonic issues.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.